ct-996 peptide 996 - Roche carmotct 996 CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist CT-996 Peptide: A Promising Oral GLP-1 Receptor Agonist for Diabetes and Obesity Management

Roche carmotct 996 The landscape of metabolic disease treatment is rapidly evolving, with a significant focus on GLP-1 receptor agonists (GLP-1 RAs)2025年8月7日—Current clinical candidates, including GSBR-1290,CT-996, and ECC5004, continue to offer substantial potential due to their oral .... Among the emerging players, the CT-996 peptide stands out as a notable investigational compound. Developed by Carmot Therapeutics and now advanced by Roche, CT-996 represents a new generation of orally administered, small-molecule GLP-1 RAs showing considerable promise for both type 2 diabetes (T2D) and obesity. This article delves into the specifics of CT-996, exploring its mechanism of action, clinical trial data, potential benefits, and its place within the broader peptide-based therapeutic arena.

Understanding CT-996: Mechanism and Development

CT-996 is characterized as an oral small molecule GLP-1 receptor agonist作者：OC Șeremet·2025—In vivo studies confirm the translational potential ofCT-996, showing rapid and sustained improvements in glycemic control, insulin secretion, and body weight .... This means it directly mimics the action of the naturally occurring incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 plays a crucial role in regulating blood glucose levels and appetiteEli Lilly - Obesity Therapies. When GLP-1 binds to its receptor, it triggers a cascade of beneficial effects, including increased insulin secretion, decreased glucagon secretion, slowed gastric emptying, and promotion of satiety.2024年7月26日—The Visible Alpha GLP-1 Drug Monitor tracks the current and projected growth of the GLP-1 (glucagon-likepeptide...CT-996in Phase 2 and Phase 1 ...

Unlike earlier injectable GLP-1 RAs, CT-996 is designed for oral administration, a significant advancement offering greater convenience and potentially improved patient adherence. The development of CT-996 involved Carmot Therapeutics' expertise in creating small-molecule GLP-1 RAs. Roche acquired Carmot Therapeutics, thereby gaining access to its pipeline, including CT-996. This acquisition underscores the significant investment and belief in the potential of this novel therapeutic.Eli Lilly - Obesity Therapies

An important aspect of CT-996's mechanism is its classification as a G protein-biased GLP-1 RA. This means it preferentially activates the G protein-coupled signaling pathway associated with GLP-1 receptor activation while potentially minimizing the recruitment of beta-arrestinGlucagon-like peptide 1 improves insulin resistance in vitro through .... This biased signaling is hypothesized to contribute to a favorable efficacy and tolerability profile, though further research is ongoing.Roche's oral GLP-1 receptor agonist CT-996 has weight ... Interestingly, CT-996 shares a similar chemical scaffold with danuglipron, an oral GLP-1 RA previously developed by Pfizer, highlighting common innovative approaches in the field.

Clinical Trial Insights and Efficacy Data

Early-stage clinical trials for CT-996 have yielded encouraging results, particularly in terms of weight management and glycemic control2024年7月17日—Roche will now focus on advancingCT-996to the second of three phases of testing on humans next year, he said. Another drug candidate known as .... In a Phase 1 study conducted in participants with obesity but without type 2 diabetes, treatment with CT-996 led to a mean weight loss of approximately -6.1% within a four-week period. Another study reported a mean weight loss of -7.3% after four weeks of treatment in a Phase 1 study. These findings suggest a rapid and substantial impact on body weight, a key outcome for individuals struggling with obesity.

Beyond weight loss, CT-996 has demonstrated potential for improving glycemic control. In vivo studies have confirmed its translational potential, showing rapid and sustained improvements in glycemic control, insulin secretion, and body weight. While specific HbA1c reductions are still being thoroughly evaluated and compared, the data suggests CT-996 could be a valuable tool for managing blood sugar levels in individuals with type 2 diabetes. The consistent efficacy observed in these early trials positions CT-996 as a strong candidate for further development. The NCT05814107 study, for instance, is specifically designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CT-996, providing crucial data for its advancement.

Potential Applications and Future Outlook

The dual action of CT-996 on both weight management and blood sugar control makes it a versatile therapeutic candidate.3天前—Multiple doses ofCT-388 were tested against a placebo over the course of 48 weeks. Roche said the shot helped people lose 22.5 percentage ... Roche has indicated that CT-996 would be used not only for blood sugar control and inducing weight loss but also potentially for long-term weight maintenancepresentation. This sustained effect is crucial, as maintaining weight loss can be challenging for many individuals.

The development of CT-996 is part of a broader trend in the pharmaceutical industry to develop more effective and convenient treatments for metabolic diseases. While injectable GLP-1 RAs like semaglutide (Wegovy, Ozempic) have demonstrated remarkable success, the advent of orally active GLP-1 RAs like CT-996 marks a significant step forward. Other oral GLP-1 RAs, such as danuglipron and ECC5004, are also in clinical development, indicating a competitive yet promising field.

Beyond direct GLP-1 agonism, research into related mechanisms is also underway. For example, studies involving GIPR antagonist antibodies conjugated to GLP-1 peptide are exploring dual-acting molecules to further enhance weight loss effects. While CT-996 focuses on the GLP-1 pathway, its success could pave the way for further innovations in receptor modulation.

Safety and Tolerability

While specific long-term safety data for CT-996 is still being gathered as it progresses through clinical trials, early reports indicate that it has been generally well-tolerated, with adverse events primarily being mild or moderate in nature. As with other GLP-1 RAs, gastrointestinal side effects are common, but the oral formulation and specific molecular design of CT-996 aim to optimize tolerability. The ongoing safety assessments in Phase 1 and subsequent phases are critical for understanding the full safety profile of this investigational drug.

Conclusion

The CT-996 peptide represents a significant development in the quest for more accessible and effective treatments for type 2 diabetes and obesity2026年1月6日—The agreement focuses on resolving Roche's concerns about potential overlaps or conflicts in intellectual property tied toCT-996. ... Protein .... As an oral small molecule GLP-1 receptor agonist, it offers the convenience of daily pill-taking combined with the potent pharmacological effects of GLP-1 agonism. Early clinical data demonstrating substantial weight loss and improvements in glycemic control are highly promising.2024年7月25日—However, early-stage trial data released last week showed that Roche's experimental once-daily pillCT-996resulted in a placebo-adjusted ... With Roche leading its development, CT-996 is poised to potentially transform how metabolic diseases are managed, offering hope for millions worldwide seeking better therapeutic options. The continued progress of CT-996 through its clinical development will be closely watched by clinicians, researchers, and patients alike.